Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.
about
Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencingA very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAARTHIV drug resistance mutations in proviral DNA from a community treatment programDeep sequencing of HIV-1 near full-length proviral genomes identifies high rates of BF1 recombinants including two novel circulating recombinant forms (CRF) 70_BF1 and a disseminating 71_BF1 among blood donors in Pernambuco, BrazilAn overview of the molecular and epidemiological features of HIV-1 infection in two major cities of Bahia state, Brazil.Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencingSwitch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy.Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic Acid.Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy.Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score.Characterization of HIV-1 Near Full-Length Proviral Genome Quasispecies from Patients with Undetectable Viral Load Undergoing First-Line HAART Therapy.HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing.Sanger and Next Generation Sequencing Approaches to Evaluate HIV-1 Virus in Blood Compartments
P2860
Q28484064-DE9A34C4-7D48-4CC4-AD1C-0500481CDFCBQ28542548-408BC231-8E03-4395-B149-383BB2C0EC36Q28543156-D7012E24-44D6-4860-BAAA-1389EE9E55F4Q28544988-DFD214A9-196A-4E16-97FB-41EE6A0DDADEQ33732319-930ADC5B-D4A2-4F44-9A77-661122D78766Q33798584-A3D5FFE6-C384-4120-9E3C-FCB64DFCC3D7Q34567556-0C77D49C-EFB4-4E65-83DF-D38C4E4612F7Q35628276-C34BC29B-1D05-4417-90CD-FFB0E697C9F5Q36426953-F591499C-A934-4287-8F91-4FB0583E05CDQ38379391-0584D716-010A-4874-9847-8889ADF6935BQ38380110-55651748-548C-43F8-A155-A5A53E47E811Q38380240-D3E23AC0-B8F0-427B-A667-80EB06EEBEB6Q38381504-FEDFB09E-646E-4A68-B7D0-81416009F4F2Q38383070-94D304D0-9675-4170-8666-FC2975EE3487Q38389563-7E1E8F36-C3BF-4CC9-8054-5BB9661EAE8DQ38936786-81C8242A-3058-4033-A947-F6C55E6EED01Q39178197-1FCFE6C5-087B-4099-94E4-180B4ACF1C37Q39980493-98552CE9-DFE8-4B4A-9507-F166A13AE4E3Q42260250-27A53118-B3D7-4BFF-AD57-73CE20533451Q47140686-5ED4D2D9-45E5-4DF9-840F-173E990C75EBQ47593950-08D8D500-2A94-41B7-AD60-0692098BDA06Q47613741-7E4FAFFF-3B05-433C-B6CC-EF7EBEE701D4Q58792426-9F148C1F-3108-4699-8A3A-CEB287773D0A
P2860
Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Historical HIV-RNA resistance ...... ppressed or residual viraemia.
@en
type
label
Historical HIV-RNA resistance ...... ppressed or residual viraemia.
@en
prefLabel
Historical HIV-RNA resistance ...... ppressed or residual viraemia.
@en
P2093
P2860
P50
P356
P1476
Historical HIV-RNA resistance ...... ppressed or residual viraemia.
@en
P2093
Anne Simon
Cathia Soulie
Cyril Clavel-Osorio
Manuela Bonmarchand
Marc Wirden
Marc-Antoine Valantin
Sidonie Lambert-Niclot
Slim Fourati
Vincent Calvez
P2860
P304
P356
10.1093/JAC/DKQ544
P407
P577
2011-01-26T00:00:00Z